Peptide Briefs

What the internet argued about in peptides this week, and what each topic means. News and commentary, not graded evidence. Every Thursday.

  • The Peptide Briefs Top Ten: Week of Oct 19, 2026

    The Peptide Briefs Top Ten: Week of Oct 19, 2026

    What the internet argued about this week, and what each topic really means.

    Every week, ten peptide topics take over the feeds, the news and the comment sections. This is the list, in order, with one line on why each matters.

    How it’s built: news coverage, Reddit and Substack discussion, and public posts on X, ordered by editorial judgment. It is not a measured ranking. I can’t measure X directly, and every claim below is attributed to its source.

    1. FDA’s interim access policy. Sent to the White House on Oct 14. The text isn’t public. Enforcement discretion is not approval, and the evidence grades haven’t moved.
    2. GLP-1 compounds. They account for most online peptide conversation, by a wide margin.
    3. Retatrutide. Lilly’s TRIUMPH-1 topline results are driving interest. The data aren’t yet peer-reviewed, and the drug isn’t approved.
    4. Platforms writing the rules. TikTok is reported to block searches for some peptide names. A screenshot of an Apple letter shows it objecting to reconstitution calculators. Neither is confirmed by the company.
    5. FDA versus “research use only.” August warning letters made the point that a disclaimer doesn’t outweigh the rest of a site’s marketing.
    6. COAs and “verified.” Everyone says the word. Few define it. Does it mean the lab confirmed the report, or the seller uploaded a PDF?
    7. Harm stories versus the access push. Media reports of people hurt by peptides are running alongside the political push for wider access.
    8. Influencer hype and expert warnings. Doctors in several countries are pushing back on social-media promotion.
    9. Access politics and polls. Sponsor-funded polling shows support for pharmacy access. Read it with the sponsor in mind.
    10. Mitochondrial peptides. MOTS-c, SS-31 and Humanin keep coming up, often with a level in the body mistaken for an outcome.

    WHAT MOVED THIS WEEK
    This is the first edition, so there is nothing to compare yet. Next week this section will show what moved up and down.

    YOUR TURN
    Which topic would you move to #1? Reply and tell me.

    Get the Top Ten every Thursday: subscribe on Substack

    I co-own a research-peptide vendor, and Peptide Briefs is editorially independent of it. Nothing here is medical advice.